Cancer Research UK is in the news for funding studies linking microbes and diet to cancer risks, highlighting ongoing efforts to improve prevention.
Recent reports reveal illegal sunbed use among children in the UK, despite laws banning under-18s. Authorities plan to strengthen enforcement, including banning unsupervised sessions and mandatory ID checks, amid rising skin cancer risks linked to UV exposure. New proposals aim to better protect youth from carcinogenic risks.
The UK government has announced a comprehensive 10-year cancer strategy aiming for 75% of patients to be cancer-free or living well after five years by 2035. The plan includes ambitious targets for diagnosis, treatment, and technological innovation, but faces significant hurdles due to workforce shortages and reliance on unproven technologies. Recent data shows current treatment delays and rising early-onset cancers threaten progress.
As of February 2026, the FDA, led by Dr. Vinay Prasad, has refused to review Moderna's new mRNA flu vaccine application, citing trial design issues, specifically the comparator vaccine used. Despite late-stage trials showing improved efficacy, the FDA demands comparison against a high-dose vaccine for seniors. Moderna plans to meet with regulators to clarify next steps. This decision reflects heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr., who has cut mRNA vaccine funding and rolled back vaccine recommendations.
Recent studies reveal colorectal cancer rates rising among adults under 65, driven by lifestyle, environmental factors, and gut bacteria toxins like colibactin. Breast cancer cases are projected to increase globally by 2050. New immunotherapy drugs show promise for advanced prostate and colorectal cancers. Experts emphasize early screening, healthy diets, and awareness to improve prevention and outcomes.
Recent reports highlight significant disparities in Medicare cost-sharing policies affecting rural hospitals and patients. Vermont hospitals face challenges in adjusting payment systems without risking legal or financial instability. Meanwhile, political debates continue over access to new cancer treatments and the impact of health policies on patient outcomes.